BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 15458824)

  • 1. The mechanism of action of platinum(IV) complexes in ovarian cancer cell lines.
    Hall MD; Amjadi S; Zhang M; Beale PJ; Hambley TW
    J Inorg Biochem; 2004 Oct; 98(10):1614-24. PubMed ID: 15458824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Axial ligands and alicyclic ring size modulate the activity and biochemical pharmacology of ammine/cycloalkylamine-platinum(IV) complexes in tumor cells resistant to cis-diamminedichloroplatinum(II) or trans-1R,2R-1S,2S-diaminocyclohexanetetrachloroplatinum(IV).
    Yoshida M; Khokhar AR; Siddik ZH
    Cancer Res; 1994 Sep; 54(17):4691-7. PubMed ID: 8062266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of amine ligands on the aquation and cytotoxicity of trans-diamine platinum(II) anticancer complexes.
    Cubo L; Quiroga AG; Zhang J; Thomas DS; Carnero A; Navarro-Ranninger C; Berners-Price SJ
    Dalton Trans; 2009 May; (18):3457-66. PubMed ID: 19381408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [1H, 15N] heteronuclear single quantum coherence NMR study of the mechanism of aquation of platinum(IV) ammine complexes.
    Davies MS; Hall MD; Berners-Price SJ; Hambley TW
    Inorg Chem; 2008 Sep; 47(17):7673-80. PubMed ID: 18671390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tetravalent platinum complexes with ammine/amine carrier ligand configuration: circumvention of platinum resistance in vivo.
    Siddik ZH; Thai G; Yoshida M; Zhang YP; Khokhar AR
    Anticancer Drug Des; 1994 Dec; 9(6):495-509. PubMed ID: 7880375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY; Rogers PM; Kelland LR
    Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigations using fluorescent ligands to monitor platinum(IV) reduction and platinum(II) reactions in cancer cells.
    New EJ; Duan R; Zhang JZ; Hambley TW
    Dalton Trans; 2009 Apr; (16):3092-101. PubMed ID: 19352538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of platinum(II)-assisted platinum(IV) substitution for the oxidation of guanosine derivatives by platinum(IV) complexes.
    Choi S; Vastag L; Larrabee YC; Personick ML; Schaberg KB; Fowler BJ; Sandwick RK; Rawji G
    Inorg Chem; 2008 Feb; 47(4):1352-60. PubMed ID: 18220340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a piperidine ligand on DNA modification by antitumor cisplatin analogues.
    Kasparkova J; Novakova O; Najajreh Y; Gibson D; Perez JM; Brabec V
    Chem Res Toxicol; 2003 Nov; 16(11):1424-32. PubMed ID: 14615968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents.
    Hamberger J; Liebeke M; Kaiser M; Bracht K; Olszewski U; Zeillinger R; Hamilton G; Braun D; Bednarski PJ
    Anticancer Drugs; 2009 Aug; 20(7):559-72. PubMed ID: 19491657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, characterization and biological activity of trans-platinum(II) and trans-platinum(IV) complexes with 4-hydroxymethylpyridine.
    Martínez A; Lorenzo J; Prieto MJ; de Llorens R; Font-Bardia M; Solans X; Avilés FX; Moreno V
    Chembiochem; 2005 Nov; 6(11):2068-77. PubMed ID: 16222727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.
    Kelland LR; Sharp SY; O'Neill CF; Raynaud FI; Beale PJ; Judson IR
    J Inorg Biochem; 1999 Oct; 77(1-2):111-5. PubMed ID: 10626362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorescent analogues of quinoline reveal amine ligand loss from cis and trans platinum(II) complexes in cancer cells.
    New EJ; Roche C; Madawala R; Zhang JZ; Hambley TW
    J Inorg Biochem; 2009 Aug; 103(8):1120-5. PubMed ID: 19564043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation of platinum(IV) complexes with dipeptide and diimine. X-ray crystal structure and 195Pt NMR spectra.
    Watabe M; Fukuda H; Kitsukawa K; Nakajima H; Yukawa Y; Igarashi S; Fujii Y; Takayama T
    J Inorg Biochem; 2006 Oct; 100(10):1653-9. PubMed ID: 16857262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multinuclear platinum(II)-amine complexes containing bis(aminopropyl)dicarba-closo-dodecaborane(12) ligands.
    Woodhouse SL; Rendina LM
    Dalton Trans; 2004 Nov; (21):3669-77. PubMed ID: 15510292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative studies on the mechanism of cytotoxic action of novel platinum II complexes with pyrazole ligands.
    Ciesielska E; Szulawska A; Studzian K; Ochocki J; Malinowska K; Kik K; Szmigiero L
    J Inorg Biochem; 2006 Oct; 100(10):1579-85. PubMed ID: 16842854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model platinum nucleobase and nucleoside complexes and antitumor activity: X-ray crystal structure of [PtIV(trans-1R,2R-diaminocyclohexane)trans-(acetate)2(9-ethylguanine)Cl]NO3.H2O.
    Ali MS; Khan SR; Ojima H; Guzman IY; Whitmire KH; Siddik ZH; Khokhar AR
    J Inorg Biochem; 2005 Mar; 99(3):795-804. PubMed ID: 15708801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, structure, and reactivity of monofunctional platinum(II) and palladium(II) complexes containing the sterically hindered ligand 6-(methylpyridin-2-yl)acetate.
    Ma Y; Day CS; Bierbach U
    J Inorg Biochem; 2005 Oct; 99(10):2013-23. PubMed ID: 16087242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversion of structure-activity relationships of antitumor platinum complexes by acetoxime but not hydroxylamine ligands.
    Zorbas-Seifried S; Jakupec MA; Kukushkin NV; Groessl M; Hartinger CG; Semenova O; Zorbas H; Kukushkin VY; Keppler BK
    Mol Pharmacol; 2007 Jan; 71(1):357-65. PubMed ID: 17050805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and characterization of the biological activity of the cisplatin analogs, cis-PtCl(2)(dexrazoxane) and cis-PtCl(2)(levrazoxane), of the topoisomerase II inhibitors dexrazoxane (ICRF-187) and levrazoxane (ICRF-186).
    Hasinoff BB; Wu X; Yang Y
    J Inorg Biochem; 2004 Apr; 98(4):616-24. PubMed ID: 15041241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.